Lanreotide Cut Neuroendocrine Tumor Progression Risk by 53% in Landmark CLARINET Trial

Phase 3, double-blind, placebo-controlled, multinational trial (CLARINET). 204 patients with well-differentiated or moderately differentiated, nonfunctioning, somatostatin receptor-positive, grade 1 or 2 (Ki-67 <10%) metastatic enteropancreatic neuroendocrine tumors were randomized to lanreotide 120 mg or placebo injected every 28 days for 96 weeks. Primary endpoint was progression-free survival.

CLARINET was the definitive trial that established lanreotide as a first-line antiproliferative treatment for well-differentiated neuroendocrine tumors, directly leading to FDA approval. Before this study, somatostatin analogs were primarily used for symptom control; CLARINET proved they actually slow tumor growth. Published in the New England Journal of Medicine, this is one of the most important studies in neuroendocrine tumor treatment.

CLARINET transformed the treatment of neuroendocrine tumors by proving that somatostatin analogs aren't just symptom management — they're actual anticancer therapy. Together with the earlier PROMID trial (which tested octreotide), it established somatostatin analogs as the foundation of neuroendocrine tumor treatment worldwide. This trial remains a cornerstone reference in oncology guidelines.

Only included grade 1/2 tumors (Ki-67 <10%) — results may not apply to more aggressive grade 3 neuroendocrine tumors. Only nonfunctioning tumors were included (those not producing excess hormones). Many patients had stable disease at entry, which could bias toward favorable outcomes. The study did not demonstrate an overall survival benefit.